Volume 132, Issue 23



December 6, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Via type I interferons, indoles limit intestinal epithelial GVHD damage. See the article by Swimm et al.

Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway
This plenary paper presents studies that elucidate the mechanisms by which PF4/heparin complexes are able to bind to circulating B-cells, providing critical new insights into the evolution of the heparin-induced thrombocytopenia immune response.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
The investigators report the final results of a phase 3 registration trial which compared the novel PI3Kδ,γ inhibitor duvelisib with ofatumumab in patients with relapsed and refractory chronic lymphocytic leukemia (CLL). They demonstrate a significant improvement in progression-free survival with duvelisib.

Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
These studies demonstrate that the tryptophan metabolite that is produced by the intestinal microbiome limits graft-versus-host disease.

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
The investigators developed a highly active checkpoint inhibitory T-cell–engaging antibody for acute myeloid leukemia by fusing the extracellular domain of programmed cell death protein 1 (PD-1ex) to a CD3 × CD33 bispecific T-cell engager (BiTE).

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
The investigators show that transplant-eligible patients with myeloma with undetectable minimal residual disease as assessed by next-generation sequencing during maintenance treatment have an excellent outcome.

Reversing anti–factor Xa agents and the unmet needs in trauma patients
In this Blood Spotlight, the authors present a perspective on andexanet alfa, an agent that recently approved by the US Food and Drug Administration that reverses the anticoagulant effects of oral factor Xa inhibitors. They discuss the utility of the drug for the clinical management of bleeding trauma patients who are on oral coagulant therapy.

Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome
The investigators make significant contributions to the knowledge on the role of BCOR in myeloid malignancy and establish a novel cooperation between TET2 and BCOR mutations in driving myelodysplastic syndromes/myeloproliferative neoplasms.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.